The thymosins-preclinical and clinical studies with fraction V and alpha-i

Richard V. Smalley, James Talmadge, Robert K. Oldham, Gary B. Thurman

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Thus, in 193 patients treated with a variety of schedules and with doses ranging from 0.6 to 960 mg/m2, fraction 5 could be administered without toxicity other than the allergic reactions noted at high repeated doses with the intermittent schedule. Significant and reproducible biologic response modification as defined by T-cell quantitation (as determined by E-rosette assay and flourescent antibody assays for T-cell surface antigens) and by lymphocyte blastogenesis to suboptimal or optimal concentrations of PHA and Con A, as well as reactions to allogeneic antigens under a variety of suboptimal and optimal conditions in standard MLR assays, could not be demonstrated. Suppressor cell activity, although not directly assayed, was not observed. Three objective tumors responses were seen in patients with renal cell carcinoma but none were seen in an adequately studied number of patients with advanced breast carcinoma, non-oat cell lung cancer, melanoma, or colon carcinoma. Alpha-1 serum levels of 10 to 25 ng/ml were achieved within one hour of the administration of 60-150 mg/m2 fraction 5. These pharmacologic levels were maintained for several hours before falling off to baseline levels by 24 hours.

Original languageEnglish (US)
Pages (from-to)69-84
Number of pages16
JournalCancer Treatment Reviews
Issue number1
StatePublished - Mar 1984
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'The thymosins-preclinical and clinical studies with fraction V and alpha-i'. Together they form a unique fingerprint.

Cite this